Astellas touts women's health with PGA sponsorship; GSK preps for global PR review;

> Astellas Pharma is turning to the PGA Tour to get women talking about their health, teeing up a sponsorship of the PGA Tour Woman initiative for the second time; the program includes on-site events at tournaments and social media. Report (sub. req.)

> GlaxoSmithKline ($GSK) is starting a global review of its public relations, PRWeek reports, aiming to shuffle its current PR roster, which now includes Burson-Marsteller and GolinHarris. Report (sub. req.)

> Medivation ($MDVN) unveiled data on its prostate cancer drug Xtandi that could lead to its use in a broader market: patients with advanced disease who haven't yet had chemotherapy. Report

> Pharma's payments to doctors are a growing concern in the U.K., where a group of physicians, researchers and campaigners are urging disclosure of gifts and payments. Report

> Should drugmakers be wary of issuing press releases about negative trial data while similar trials are still ongoing? Report

And Finally... Can Big Data help drugmakers keep patients on their pills--and refills coming? Report

Suggested Articles

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.